ArticleScience immunology2018
Inhibitory killer cell immunoglobulin-like receptors strengthen CD8
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 68 citations in OpenAlex.
- Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.JCI insight · 2021Trial
- Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.Blood advances · 2026Article
- NK-like and networked CD8bioRxiv : the preprint server for biology · 2026Article
- Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.Haematologica · 2026Article
- Review
- Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.Frontiers in immunology · 2025Article
- Inhibitory KIRs decrease HLA class II-mediated protection in Type 1 Diabetes.PLoS genetics · 2024Article
- Biologically-informed killer cell immunoglobulin-like receptor gene annotation tool.Bioinformatics (Oxford, England) · 2024Article
- Genetic complexity of killer-cell immunoglobulin-like receptor genes in human pangenome assemblies.Genome research · 2024Article
- Biologically-informed Killer cell immunoglobulin-like receptor (KIR) gene annotation tool.bioRxiv : the preprint server for biology · 2024Article
- Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules.Structure (London, England : 1993) · 2024Article
- Modelling HIV-1 control and remission.NPJ systems biology and applications · 2024Review
- Using In silico models to predict lymphocyte activation and development in a data rich era.Immunoinformatics (Amsterdam, Netherlands) · 2024Article
- Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.British journal of haematology · 2024Article
- NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells.Cell reports · 2024Article
- Germline natural killer cell receptors modulating the T cell response.Frontiers in immunology · 2024Review
- DonorFrontiers in immunology · 2024Article
- Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Blood advances · 2023Article
- Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.Science immunology · 2023Article
- Negativity begets longevity in T cells.The Journal of clinical investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 11 institutions in 3 countries.
Lies BoelenDepartment of Medicine, Imperial College London, London, UK.ORCID 0000-0003-3786-5545
Bisrat DebebeDepartment of Medicine, Imperial College London, London, UK.ORCID 0000-0002-6551-5641
Marcos SilveiraDepartment of Medicine, Imperial College London, London, UK.
Arafa SalamInstitute for Infection and Immunity, St. George's, University of London, London, UK.
Julia MakindeInternational AIDS Vaccine Initiative Human Immunology Laboratory, London, UK.ORCID 0000-0002-9906-7437
Chrissy H RobertsClinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-1064-5980
Eddie C Y WangDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0002-2243-4964
John FraterNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-7163-7277
Jill GilmourInternational AIDS Vaccine Initiative Human Immunology Laboratory, London, UK.
Katie TwiggerDepartment of Medicine, Imperial College London, London, UK.
Kristin LadellDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0002-9856-2938
Kelly L MinersDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Jyothi JayaramanImmunology Division, Department of Pathology, University of Cambridge, Cambridge, UK.
James A TraherneImmunology Division, Department of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-6003-8559
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0001-9416-2737
Ying QiCancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Maureen P MartinCancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-0990-3500
Derek C MacallanInstitute for Infection and Immunity, St. George's, University of London, London, UK.ORCID 0000-0002-3014-7148
Chloe L ThioJohns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-8851-8319
Jacquie AstemborskiJohns Hopkins University, Baltimore, MD, USA.
Gregory KirkJohns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-7829-1405
Sharyne M DonfieldRho, Chapel Hill, NC, USA.
Susan BuchbinderSan Francisco Department of Public Health, San Francisco, CA, USA.
Salim I KhakooFaculty of Medicine, University of Southampton, Southampton, UK.ORCID 0000-0002-4057-9091
James J GoedertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-6134-1472
John TrowsdaleImmunology Division, Department of Pathology, University of Cambridge, Cambridge, UK.
Mary CarringtonCancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-2692-2180
Simon KollnbergerDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0002-6904-3397
Becca AsquithDepartment of Medicine, Imperial College London, London, UK. b.asquith@imperial.ac.uk.ORCID 0000-0002-5911-3160
Imperial College London · GBCardiff University · GBJohns Hopkins University · USLeidos (United States) · USUniversity of Cambridge · GBInternational HIV/AIDS Alliance · GBSan Francisco Department of Public Health · USSt George's, University of London · GBLondon School of Hygiene & Tropical Medicine · GBNational Cancer Institute · USUniversity of Oxford · GB
Funding
Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI LETVIN, NORMAN L · 2006 to 2011
$290.5MThe AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9MINCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5MViral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI LETVIN, NORMAN L · 2005 to 2005
$14.9MHIV and Hepatitis C Pathogenesis & The Human GenomeR01DA013324 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 1999 to 2018
$12.0MMolecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8MPathogenesis of HIV and HCV in Hemophilia: HGDSR01HD041224 · NICHD · CHILDREN'S HOSPITAL LOS ANGELES · PI GOMPERTS, EDWARD DAVID · 2001 to 2004
$2.8MPatient-Oriented Research and Mentorship in HIV and Non-Communicable DiseasesK24AI118591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2015 to 2019
$766kMedical Research Council G0601072Medical Research Council G0901682Medical Research Council G1001052Medical Research Council MR/J007439/1Medical Research Council MR/L006588/1Medical Research Council MR/L018373/LMedical Research Council MR/M019829/1Medical Research Council MR/P001602/1Medical Research Council MR/P011233/1NIAID NIH HHS K24 AI118591NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NICHD NIH HHS R01 HD041224NIDA NIH HHS R01 DA012568NIDA NIH HHS R01 DA013324NIDA NIH HHS U01 DA036297Wellcome TrustWellcome Trust 090323/Z/09/ZWellcome Trust 100326Z/12/ZWellcome Trust 103865Z/14/ZWellcome Trust 105609/Z/14/Z
Abstract
Killer cell immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer cells, where they play a key role in the regulation of innate immune responses. Recent studies show that inhibitory KIRs can also affect adaptive T cell-mediated immunity. In mice and in human T cells in vitro, inhibitory KIR ligation enhanced CD8
Indexed as
CD8-Positive T-LymphocytesHepacivirusHIV-1HumansHuman T-lymphotropic virus 1Receptors, KIRReceptors, KIR
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.